Enovis Corp (ENOV) Cash Flow Statement

A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.

Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments.

Total Cash From Operating Activities Chart for Enovis Corp

Enovis Corp (ENOV) operating cash flow for FY2025 was USD 217.3M, a 91.4% change from FY2024. Enovis Corp's operating cash flow moved from USD -7.8M in 2005 to USD 217.3M in 2025 over 20 years. Operating cash flow compound annual growth rate: 5-year CAGR of -6.4%, 10-year CAGR of -3.3%.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Cash From Operating Activities (US Dollars)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
$1.22B
Implied Share Price
$21.08
Enterprise Value
$2.41B
Revenue (TTM)
$2.30B
EBITDA
$379.78M
Profit Margin
-47.97%
Trailing P/E
—
Forward P/E
4.64
Price/Book (MRQ)
0.71
Price/Sales (TTM)
0.53
EV/EBITDA
22.42
EV/Revenue
1.05
Dividend Yield
—
Book Value
$25.61
Free Cash Flow (FY2025)
$19.92M
Free Cash Flow Yield
1.64%

Snapshot as of 24th October 2026 — not point-in-time controlled, may lag the live market by a few days.